Supplementary material

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan

*Corresponding author* Director, Department of Urology, Harasanshin Hospital, 1-8 Taihakumachi, Hakata-ku, Fukuoka 812-0033, Japan; Tel: +81-92-291-3434; Fax: +81-92-291-3424; yokoa@harasanshin.or.jp
List of investigators

Hirokazu Abe, Haruhito Azuma, Shin Egawa, Satoshi Fukasawa, Hiroshi Fukuhara, Ryouhei Hattori, Taro Iguchi, Yukio Kageyama, Sojun Kanamaru, Jun Miki, Takashi Murata, Masayoshi Nagata, Kazuo Nishimura, Norio Nonomura, Eiyu Nozawa, Kenji Numahata, Tetsuo Okuno, Ataru Sazawa, Nobuaki Shimizu, Hiroaki Shimmura, Tatsuya Shimomura, Yutaka Takezawa, Toshiki Tanikawa, Yoshinori Taoka, Hiroji Uemura, Masahiro Uno, Masahiro Yashi, Akira Yokomizo, Junji Yonese
**Supplementary Table 1** New antineoplastic therapies initiated during the observation period

| Antineoplastic therapy\(^a\)     | Patients, \(n\) (%) |
|---------------------------------|---------------------|
|                                 |                     |
| Antineoplastic therapy\(^a\)    | 70 (34.1)           |
| Chemotherapy                    | 22 (31.4)           |
| Hormone therapy                 | 46 (65.7)           |
| Radiopharmaceutical             | 2 (2.9)             |

\(^a\)Analysis set: \(n = 205\)
**Supplementary Table 2** Cytotoxic chemotherapies used during the observation period

| Cytotoxic chemotherapy\(^a\) | Patients, n (%) |
|-----------------------------|-----------------|
|                             | 41 (20.0)       |
| Docetaxel                   | 31 (75.6)       |
| Estramustine                | 10 (24.4)       |
| Cabazitaxel                 | 0               |
| Tegafur/uracil              | 0               |
| Endoxan                     | 0               |

\(^a\)Analysis set: \(n = 205\)
**Supplementary Table 3** Treatment duration of enzalutamide by index date

| Analysis set | Patients, n (%) | Treatment duration of enzalutamide | Median (IQR, months) |
|--------------|----------------|-----------------------------------|---------------------|
|              |                | ≤6 months to ≤1 year              | >6 months to ≤1 year | >1.5 years to ≤2 years | >2.5 years to ≤3 years | >3 years to ≤3.5 years | >3.5 years |
|              |                | ≤6 months | >6 months | >1 year | >1.5 years | >2.5 years | >3 years | >3.5 years |
|              |                | 205       | 45        | 52      | 30        | 25        | 17       | 21        | 12        | 3         | 13        |
|              | (100.0)        | (22.0)    | (25.4)    | (14.6)  | (12.2)    | (8.3)     | (10.2)   | (5.9)     | (1.5)     | (7–24)    |

| Index date | Nov 2014 to Mar 2015 | Apr 2015 to Sep 2015 | Oct 2015 to Mar 2016 | Mar 2016 | Apr 2016 to Sep 2016 |
|------------|----------------------|----------------------|----------------------|----------|----------------------|
|            | 24 (11.7)            | 33 (16.1)            | 37 (18.0)            | 37 (18.0)| 24 (11.7)           |
|            | (33.3)               | (15.2)               | (18.9)               | (18.9)   | (33.3)               |
|            | (12.5)               | (3.0)                | (16.2)               | (16.2)   | (8.3)                |
|            | 6 (25.0)             | 4 (12.1)             | 2 (5.4)              | 4 (10.8) | 3 (12.5)            |
|            | (4.2)                | (6.1)                | (5.4)                | (10.8)   | (12.5)               |
|            | 1 (4.2)              | 5 (15.2)             | 4 (10.8)             | 3 (8.1)  | 8 (33.3)            |
|            | (4.2)                | (15.2)               | (10.8)               | (8.1)    | (33.3)               |
|            | 1 (4.2)              | 5 (15.2)             | 15 (40.5)            | 15 (40.5)| 8 (33.3)            |
|            | (4.2)                | (15.2)               | (40.5)               | (40.5)   | (33.3)               |
|            | 3 (12.5)             | 2 (8.3)              | 3 (12.5)             | 3 (12.5) | 16 (33.3)           |
|            | (12.5)               | (8.3)                | (12.5)               | (12.5)   | (33.3)               |
|            |                      |                      |                      |          | (5–26)              |
|         | Count | IQR | Median | Mean | Oct 2016 to Mar 2017 | Apr 2017 to Sep 2017 | Oct 2017 to Mar 2018 |
|---------|-------|-----|--------|------|----------------------|----------------------|----------------------|
| Oct 2016 to Mar 2017 | 24 (11.7) | 3 (12.5) | 5 (20.8) | 1 (4.2) | 15 (62.5) | 20 (12–21) |
| Apr 2017 to Sep 2017 | 28 (13.7) | 6 (21.4) | 8 (28.6) | 14 (50.0) | 12 (7–16) |
| Oct 2017 to Mar 2018 | 35 (17.1) | 8 (22.9) | 27 (77.1) | 8 (6–9) |

*IQR* interquartile range
Supplementary Fig. 1 Time to first use of new antineoplastic therapy

| Analysis set (n) | Patients receiving antineoplastic therapy, n (%) | Median (95% CI), months |
|------------------|-----------------------------------------------|------------------------|
| All patients (n = 205) | 70 (34.1) | 36 (27–NR) |

No. at risk

All patients 205 183 159 118 105 86 65 45 36 22 9 4

CI confidence interval; NR not reached
**Supplementary Fig. 2** Time to first use of cytotoxic chemotherapy

| Analysis set (n) | Patients receiving cytotoxic therapy, n (%) | Median (95% CI), months |
|------------------|------------------------------------------|------------------------|
| All patients (n = 205) | 41 (20) | NR (41–NR) |

No. at risk

All patients 205 137 78 27 7

*CI* confidence interval; *NR* not reached
Supplementary Fig. 3 MFS in (a) all patients and (b) subgroup analysis by median PSA at index date
CI confidence interval; MFS metastasis-free survival; PSA prostate-specific antigen; NR not reached